Freeman Technology highlights relevance of the FT4 for DPI characterisation
Respiratory Drug Delivery (RDD) 2010, 25 - 29 April 2010, Florida, US
Dynamic powder characterization with the FT4 directly quantifies powder flowability and the response of a formulation to air, a critical property for successful DPI development. To ensure efficient drug delivery a DPI formulation/device combination must be engineered to achieve aerosolisation of the dose to a respirable size during use.
Research at the University of Bath has shown a robust correlation between FPD and aerated energy, a measure of how the flowability of the powder changes with the amount of air flowing through it. This makes the FT4 an extremely useful tool for the development of DPI formulations, which are required to disperse easily, with more consistent and less patient dependent performance.
The FT4 combines dynamic testing methodologies with shear and bulk property measurement, to provide comprehensive, process relevant powder characterisation. Precision engineering in combination with well-defined, automated test procedures deliver exceptional reproducibility and sensitivity. With application know-how that has been gained from 10 years working with industry, Freeman Technology also provides extensive powder processing expertise alongside the FT4 Powder Rheometer.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Regulatory
WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory
FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus
AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory
FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection
The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026